morning, everyone. good and Prahlad, Thanks,
earnings pleased in remains focus conversion to free year-to-date, we're As Prahlad truly generation to continued mentioned, flow our exceed as our cash also cash the is for adjusted see performance. we was which income outstanding performed third net to and I again quarter. quarter, our extremely the XXX% on well able expectation
Pharma/biotech with and under down continue China more life in year-over-year overall. returning while our demand for reagents, stable had anticipated pressure, growth continue remain to than instruments sciences was we particularly to remain
immunodiagnostics. our strong performance reproductive across and This was offset diagnostics both health businesses in by
the look have in as we towards is in worst continuing we last growth path feel recovery been more behind to years over ahead, As the likely X us that future. rates pressure is its demand the normalized under which continue markets the the
Our a consistently Software high innovation Diagnostics level, strong very execution. and strong trends, at significant to commercial and perform continue businesses their underlying market given
continue, given quarter have year. quarter, with a became anticipate more our buyback sheet flow strong will and we our we likely suggested in this we performance activity balance the As cash which active ago,
our extremely near term remains for returns being more the and future bright, shareholders. in significant our provide believe aggressive we Our with will repurchases
turning third Now the to performance. quarter of specifics our
neutral Overall, from the no acquisitions. in expectations. company growth FX line and our $XXX in organic revenue, generated had with growth, total contribution adjusted X% was incremental the in in million quarter we resulting revenues to which of was again
third quarter P&L, in relates and basis the dollar margins relatively keep resulting it which were As We able up flat roughly our sequentially versus XX operating XXXX expectations. to strong our on adjusted again incrementals. expenses XX.X% we significantly above in a quarter, operating was points to basis, our generated
impressed by which I rate industry-leading continue expand on the recover. impact as margins to I us demand to actions our structure, an be allow believe should industry expense continues are team's at to our having
Looking cash interest inflows and adjusted we the expense and interest fixed as below million from our net line, are the other $X favorable against in strong quarter the benefiting environment rate our debt. was our
initiatives. favorable rate adjusted tax was which to our the planning recent the tax of was quarter, our impact expectations lower XX.X% Our in due than
was With $X.XX $XXX expectations. the for the in an of in average adjusted quarter, third which EPS diluted this million resulted of quarter above our share $X.XX, count
We a perspective of $XXX year-to-date continue to spot P&L. XXX% flow a remains the generated capital. from working $XXX another conversion manage cash the This bright the tools quarter. fine-tuning our net AI-based processes adjusted flow free beyond brings generated in we and to to in of allow us resulting strong internal Moving as cash income. we million, million cash that leverage had appropriately a Cash as free quarter
Considering approximately payments accounting expect received cash recent performance, we already divestiture. flow year-to-date to approximately resulting million when additional our this in for cash $XXX total to related strong cash the $XXX inflows be million free now generation of
remained active our total October, by we million As shares. the Through repurchasing deployment, over is third quarter as million. on of worth buybacks for $XXX in capital mentioned, spend I $XXX
of previous received a intention our recently to billion left on also $X our continue remain authorization provides Given active our debt and our repurchases. of repurchase authorization what the flexibility the with $XXX was debt to with us from to leverage that share due with which remain ratio quarter adjusted new aggressive replaced Board, net retiring We came the buyback, roughly a we to after finished in EBITDA X.Xx mid-September. million
rate interest XXX% with fixed is weighted X.X% another of X.X a positioned with Our rate strongly balance debt years. and sheet average out maturity
flexible the evaluate As investment-grade we order continue return our capital will rating. capitalize credit while remain to maintaining we opportunities highest on in to deployment,
provide our in trends, Sciences X% I business of website. slide a in commentary will is quarterly Investor in quarter X% decline comprised third some included X% Life the the Relations The in on organic revenue now which also our and growth growth quarter segment presentation on Diagnostics. in our was
in grew From Americas flattish and X% on Asia X% revenue China both the organic low million while an a single on digits declining of we was basis. quarter. basis in digits. This segment our reported $XXX Geographically, with generated perspective, Life business Sciences down and adjusted a was the single in the low Europe,
the quarter. and customers academic customer and in From low government in single the a perspective, pharma/biotech digits to declined both sales customers
and modestly a expectations. the reagents grew quarter line were Our basis, life dollar mid-single with in up the our digits on in sequentially science in
in Our mentioned, worse year-over-year, teens was revenue as which, low than Life Science declined anticipated. the instruments
mid-single headwinds faced software business as declined Signals Our to in timing renewals. relating digits the of the it known
We digits quarter, continue expected to in resulting double to still low strong in full overall. expect the the for growth the very be Signals for year organic fourth business performance the in
all mid-single with high during generated on our The our growth quarter, X% continues X% million with business basis. adjusted grew digits and organic well the Diagnostics in year-to-date our to a in segment, perform $XXX to of a low organically basis quarter, double-digit perspective, up was business a reported an across expectations. the single- From basis. in revenue we In business Immunodiagnostics line on the which regions on
in the quarter. the Our single Reproductive grew high organically business Health digits in
driven and commercial continued global outstanding given rates. grew to Newborn screening in the by double-digits perform the well continued is globally in headwinds and execution, low operational which birth the quarter from
in with the region. had anticipated, Dragon Year in the a related year-over-year we to our in newborn improved saw and improvements results prenatal we and of both the As quarter sequential the businesses
over the the Applied declines, in our that modest quarter declined its mid-single in After resulted in low sign Genomics years fairly in of X had quarter, Finally, being was double-digit now this the revenues third business digits another up promising the which stabilized. consistent business sequentially. single decline total digits
here recovery. We expect path now quarter headed its fourth year-over-year the improve performance to business as solidly on again to appears toward in be this right the
below low which in high approximately overall, pertains declined it an in This to and for the our Sciences. consisted China revenue expectation. flat specifically, As flat performance of country year-over-year single-digit Life our Diagnostics the single-digits was modestly a decline in
offset for Sciences, Life growth to we by in capital customers as stimulus on Within reagents, a their recent of double-digit purchases Based ahead decline arriving. instrumentation, saw feedback equipment a continue to strong beyond. this in that impact behavior from going we teams, continue eventually impact XXXX confident is largely the will remain but region, customer stimulus our to believe delay positively have we and an in
where continuing pharma/biotech to gradually the for those of our to of outside fourth across activity our quarter, customer outlook seeing improve. regards are most In strong businesses performance we is
normal continues lower to patterns we demand customers as pickup yet, we the not that than return historically in remain these Given been. end-of-year spending that to assuming more are seeing of now it capital for typical equipment has are
This assumptions our outlook X% last in X% over $X.XX the in revenue range being expected our given for to quarter currency fourth our is outlook the resulting approximately updated to be growth of year With XXXX growth X%, full in organic organic to months, the $X.XX to which this for updated to the the brings few now of range brings X%. billion. weaker year billion dollar full
adjusted margin able of see performance lower operating in outlook adjusted little that to are to outlook, our quarter be expected great continue this reiterate translates very modestly range margins to and be for we a This a our have our to fourth year. margins the overall to in is revenue it XX%. over to strong a Despite XX.X% XX% operating to
our $XX cash estimate net of prior approximately expect making are us from approximately other progress good our down year, management, the and earlier, million and expense highlighted for to interest now expense $XX interest our to we I on As allowing generation million. be
are and execution making this our in outlook. now our operating prior We XXXX year XX% good With below-the-line progress rate are result from new full range earnings strong we initiatives. a our our to adjusted tax tax our share planning raising margin per also good to on outlook progress items, to $X.XX of adjusted expect approximately guidance $X.XX. to XX%, be on year We down full
on, in touched cash significantly outlook year. this million, flow coming expect quite approximately $XXX this from earnings increased strong result to working to already outlook I've free up into performance As now capital and our we our be our
this a another to cash, business year generated cash approximately our $XXX had this software addition recent our Overall, to well, received Science businesses quarter divestiture. internally executing so we and have as and to improve. performing we third continue are gradually and our in strong are far In Life also very related million well diagnostics
year and guidance accretively We our generating us are are raise year-over-year to expanding to of adjusted the which this allowing for significant amounts we margins cash, use, earnings year. putting
I can joining its Revvity, look San what many future out so we forward makes more are in to of and so a in us weeks excited our Diego, about that about few why and potential. unique you learn us you
to With call open up questions. that, operator, we like would now the for
